PHRX Stock Overview
Pharmagen, Inc. distributes specialty drugs to hospitals, acute care facilities, surgery centers, and other healthcare practitioners in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Pharmagen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -99.00% |
| 3 Year Change | -99.87% |
| 5 Year Change | -99.83% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| PHRX | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0% | 2.1% | 1.2% |
| 1Y | -99.0% | 3.6% | 24.7% |
Return vs Industry: PHRX underperformed the US Healthcare industry which returned 4% over the past year.
Return vs Market: PHRX underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| PHRX volatility | |
|---|---|
| PHRX Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PHRX has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PHRX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | www.pharmageninc.com |
Pharmagen, Inc. distributes specialty drugs to hospitals, acute care facilities, surgery centers, and other healthcare practitioners in the United States. The company sources and distributes specialty drugs, blood plasma derivatives, specialty products, vaccines, anti-infectives, and hard-to-find pharmaceuticals. It offers plasma derivatives for treating serious medical conditions, such as cancer, hemophilia, rheumatoid arthritis, multiple scleroses, blood disorders, hepatitis, and HIV; and specialty products for treating respiratory, oncology, cardiovascular, and hormonal syndromes.
Pharmagen, Inc. Fundamentals Summary
| PHRX fundamental statistics | |
|---|---|
| Market cap | US$517.00 |
| Earnings (TTM) | -US$6.43m |
| Revenue (TTM) | US$4.41m |
0.0x
P/S Ratio0.0x
P/E RatioIs PHRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHRX income statement (TTM) | |
|---|---|
| Revenue | US$4.41m |
| Cost of Revenue | US$1.66m |
| Gross Profit | US$2.75m |
| Other Expenses | US$9.18m |
| Earnings | -US$6.43m |
Last Reported Earnings
Mar 31, 2014
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did PHRX perform over the long term?
See historical performance and comparison